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titutotumAbstract Little is known of cancer rehabilitation needs in Europe. EUROCHIP-3 organised
a group of experts to propose a list of population-based indicators used for describing cancer
rehabilitation across Europe. The aim of this study is to present and discuss these indicators.
A EUROCHIP-3 expert panel reached agreement on two types of indicators. (a) Cancer prev-
alence indicators. These were proposed as a means of characterising the burden of cancer
rehabilitation needs by time from diagnosis and patient health status. These indicators can
be estimated from cancer registry data or by collecting data on follow-up and treatments
for samples of cases archived in cancer registries. (b) Indicators of rehabilitation success.
These include: return to work, quality of life, and satisfaction of speciﬁc rehabilitation needs.
Studies can be performed to estimate these indicators in individual countries, but to obtain
comparable data across European countries it will be necessary to administer a questionnaire
to randomly selected samples of patients from population-based cancer registry databases.
However, three factors complicate questionnaire studies: patients may not be aware that they
have cancer; incomplete participation in surveys could lead to bias; and national conﬁdential-
ity laws in some cases prohibit cancer registries from approaching patients. Although these
studies are expensive and difﬁcult to perform, but as the number of cancer survivors increases,
it is important to document their needs in order to provide information on cancer control.
 2012 Elsevier Ltd. All rights reserved.lsevier Ltd. All rights reserved.
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Cancer survival is increasing in Europe as a result of
early diagnosis and improved treatment,1 with the corol-
lary that the proportion of persons in the population
with a (past) diagnosis of cancer is growing. According
to RARECARE estimates – based on cancer registry
data – there were 3566 persons per 100,000 with a diag-
nosis of any type of cancer in the European Union on
1st January 2003, equivalent to a total prevalence of
nearly 17.8 million.2 The number of prevalent cancer
cases is projected to increase as the European popula-
tion continues to age, as cancer incidence increases,
and as survival improves.3 EUROCARE estimated that
the proportion of patients (diagnosed from 1988 to
1999) considered cured of their cancer (all cancers com-
bined) varied between 38% and 59% in women, and 21%
and 47% in men, by country.4
Cancer is often a chronic condition and patients may
endure physical and psychological symptoms for years
after their treatment is complete.5 Such symptoms can
worsen the quality of life, and include pain, fatigue,Table 1
List of cancer rehabilitation indicators considered and eventually adopted
Domain Initial list
(before ﬁrst meeting)
I
(
(i) Cancer rehabilitation
needs
Prevalence (total and by years
from diagnosis)
P
y
Proportion of patients with
relapses
P
w
(ii) Prominence/presence
of cancer
rehabilitation on
political and clinical
agendas
A
–
D
–
–
(iii) Cancer
rehabilitation
capabilities
(structures, services
and funding)
Availability of A
– Counselling –
– Psychological support
– Homecare –
–
–
– Psychological support
– Nutritional counselling
– Social care workers
– Exercise programmes
Funding for rehabilitation F
r
(iv) Measures of
rehabilitation success
Return to work R
Q
p
Indicators of rehabilitation needs
according to cancer sitecognitive impairment, worries about health, irritablemood,
demoralization, depression and interpersonal problems.5
The Council of Europe has recognised that reducing
the cancer burden in Europe will require an integrated
approach to cancer control and has noted that ‘to attain
optimal results a patient-centred, comprehensive inter-
disciplinary approach and optimal psycho-social care
should be implemented in routine cancer care, rehabili-
tation, post-treatment and follow-up’.6
To provide data in the area of cancer rehabilitation
needs, as part of its work-package 6 (WP-6) initiative,
the European Cancer Health Indicator Project (EURO-
CHIP-3)7 recruited a group of unpaid experts to draw
up a list of plausible population-based indicators able
to describe cancer rehabilitation in Europe. The panel
adopted the broad deﬁnition of rehabilitation proposed
by the WHO: ‘a process aimed at enabling patients to
reach and maintain their optimal physical, sensory,
intellectual, psychological and social functional levels’.8
The panel also adopted a broad deﬁnition of cancer sur-
vivors: the total prevalence of persons in the population
with a diagnosis of cancer.list.
ntermediate list
after ﬁrst questionnaire)
Final list
(after last meeting)
revalence (total and by
ears from diagnosis)
Prevalence (total and by years
from diagnosis)
roportion of patients
ith relapses
Proportion of cured and
diﬀerentiated prevalence
vailability of
National Policy
ocuments
Guidelines
Training courses
vailability of
Counselling
Homecare
FU programmes
NGOs
unding for
ehabilitation
eturn to work Return to work
uality of life of cancer
atients
Quality of life of cancer patients
Indicators of rehabilitation needs
according to cancer site:
– Speech and language therapy
for head and neck cancer patients
– Physiotherapy for breast cancer
patients
– Dietary advice for colorectal
cancer patients
– Psychological support for all
cancer patients
1358 P. Baili et al. / European Journal of Cancer 49 (2013) 1356–1364The aims of the present article are: (a) to describe the
candidate indicators evaluated by the expert panel; (b)
to present the ﬁnal list of indicators proposed by the
panel and (c) to present the results of a literature survey,
undertaken after deﬁnition of the ﬁnal list, to ﬁnd Eng-
lish language scientiﬁc articles concerned with methods
for estimating the proposed indicators.
2. Materials and methods
2.1. Work of the panel – production of indicators
Work on cancer rehabilitation indicators started in
2009 and concluded in the early months of 2012. During
that time 37 experts on cancer rehabilitation (public
health professionals, epidemiologists, palliative care
professionals, oncologists, clinical psychologists and
other physicians) from the 27 European Union member
states were recruited to the WP-6 panel. The work of the
panel proceeded by meetings. Five meetings were held.9
Before the ﬁrst meeting, the WP-6 coordinator group
prepared a list of possible rehabilitation indicators for
consideration (Table 1, column 2). Between meetings,
panel members carried out their own literature searches
to ﬁnd data on the indicators suggested. Also between
meetings two ad hoc questionnaires were sent out to
panel members soliciting further information and opin-
ions (particularly from members not present at the pre-
vious meeting). The questionnaires, available online,10
were devised by the WP-6 coordinator group typically
in response to matters arising or decisions taken during
previous meetings. The ﬁrst questionnaire went out in
April–June 2010 and solicited opinions on deﬁnitions,
methods of determining and sources of data for estimat-
ing the indicators being considered. The second ques-
tionnaire, sent out in January–September 2011,
solicited information for assessing the feasibility of using
(estimating) the indicators being considered for
adoption.
2.2. Criteria for selecting ﬁnal list of indicators
It was agreed that any cancer rehabilitation indicator
proposed must: (a) be available or estimable for entire
populations; (b) describe the same aspect of cancer reha-
bilitation in all European countries and (c) be collectable
by standardised methods in all countries.
Indicators were initially sought in the following
domains: (i) cancer rehabilitation needs; (ii) promi-
nence/presence of cancer rehabilitation on political
and clinical agendas; (iii) cancer rehabilitation capabili-
ties (structures, services and funding) and (iv) measures
of rehabilitation success. Table 1 shows the indicators
discussed and eventually adopted by the expert panel.
The last column shows the ﬁnal indicators proposed
by the panel.2.3. Systematic literature search
In order to ﬁnd articles describing methods for esti-
mating the indicators included in the ﬁnal list, we carried
out a systematic literature search in February 2012 using
PubMed.11 We ﬁrst decided the search terms (ﬁrst col-
umn, Table 2). We next examined abstracts of articles
found, to identify those potential pertaining to indica-
tors. Finally we read the Materials and Methods of arti-
cles apparently pertaining to indicators and selected
those that were pertinent. Table 2 shows results of the
PubMed search.3. Results
3.1. Indicators on cancer rehabilitation needs
The expert panel found that the indicator best able to
quantify patients with rehabilitation needs was total
prevalence.12 This indicator can be estimated from can-
cer registry data12 or through mathematical modelling
of mortality and survival data.13 The EUROPREVAL14
and RARECARE2 projects produced estimates of total
prevalence by cancer site in Europe in 1992 and 2003,
respectively. Total prevalence comprises recently-
diagnosed patients, those undergoing treatment or fol-
low-up and also long-term survivors, some of whom
may be considered cured. It is useful to divide total prev-
alence into subgroups of cancer survivors having partic-
ular needs. One subdivision is according to time elapsed
from diagnosis (e.g. two-year prevalence, ﬁve-year prev-
alence, which refers to survivors with diagnosis, respec-
tively, in the two and ﬁve years preceding the prevalence
index date).13,14 Years from diagnosis to reference date
identiﬁes (is a useful proxy for) groups of patients with
diﬀering healthcare needs. A study on prevalence by
years from diagnosis was recently performed in the Uni-
ted Kingdom (UK).15 GLOBOCAN16 produced Eur-
ope-wide estimates of ﬁve-year prevalence for 2008.
We found 40 other scientiﬁc articles dealing with popu-
lation-based cancer prevalence in Europe (Table 2).
It is also possible to apply cured models to cancer
registry data to estimate the proportion of cured patients.
This is the fraction of the total prevalence consisting of
patients with the same life expectancy as the general
population of the same age and sex; the remaining frac-
tion consists of patients who will die of their disease and
who may have diﬀerent healthcare needs from cured
patients. The proportion of cured patients indicator
has been estimated by EUROCARE for all cancers
combined and various cancer sites for several European
countries.4
It is also useful to identify other sub-groups of preva-
lent cases according to their clinical situation and likely
demands on health care facilities. To do this, cancer
Table 2
Results of PubMed searcha for articles on population-based methods for collecting data on ﬁnal list of cancer rehabilitation indicators.
Search terms No. articles Indicator No. articles pertaining to Europe
(“prevalence” [MeSH term] OR (“Survivors/statistics and numerical
data” [MAJR]) OR (“Survival analysis” [MeSH term] AND
(“cure” [all ﬁelds] OR “prevalence” [all ﬁelds]))) AND
(Cancer[title/abstract] OR neoplasm[title/abstract]) AND
(“cancer registry” [all ﬁelds] OR “population-based” [all ﬁelds]
OR “estimate” [all ﬁelds] OR “estimating” [all ﬁelds] OR “model”
[all ﬁelds] OR “modelling” [all ﬁelds])
1977 Prevalence (total and by time) 40
Cured prevalence 4
Diﬀerentiated prevalence 3
(“Employment/statistics and numerical data” [MAJR] OR “Sick
Leave/statistics and numerical data” [MAJR] OR “Survivors/
statistics and numerical data” [MeSH term] OR “workplace” [MeSH
term] OR “work schedule tolerance” [MeSH term] OR “work
capacity evaluation” [MeSH term] OR “return to work” [title]) AND
(cancer[title/abstract] OR neoplasm[title/abstract]) AND (“work”
[all ﬁelds] OR “employment” [all ﬁelds] OR “retirement” [all ﬁelds])
424 Return to work 12
((“quality of life” [MAJR] OR “survivors/psychology” [MAJR] OR
“quality of life/psychology” [MAJR]) AND (cancer[title/abstract]
OR neoplasm[title/abstract])) OR ((“neoplasms” [MeSH terms])
AND (“rehabilitation” [all ﬁelds] OR “psychological” [all ﬁelds]))
AND (“cancer registry” [all ﬁelds] OR “population-based”
[all ﬁelds])
438 Quality of life 41
Psychological support for all
cancer patients
2
(“head and neck neoplasms” [MeSH term]) AND (“rehabilitation”
[all ﬁelds] OR “speech” [all ﬁelds] OR “language” [all ﬁelds])
AND (“cancer registry” [all ﬁelds] OR “population-based”
[all ﬁelds])
10 Speech and language therapy for
head and neck cancer patients
(“breast neoplasms” [MeSH term]) AND (“rehabilitation” [all ﬁelds]
OR “physiotherapy” [all ﬁelds]) AND (“cancer registry” [all ﬁelds]
OR “population-based” [all ﬁelds])
23 Physiotherapy for breast cancer
patients
(“colorectal neoplasms” [MeSH term] OR “colon neoplasms” [MeSH
term] OR “rectal neoplasms” [MeSH term]) AND (“rehabilitation”
[all ﬁelds] OR “dietician” [all ﬁelds]) AND (“cancer registry” [all
ﬁelds] OR “population-based” [all ﬁelds])
13 Dietary advice for colorectal
cancer patients
a Three-phase search strategy: (1) deﬁnition of search terms; (2) examination abstracts to identify articles possibly pertaining to indicators; (3) reading of Materials and Methods of articles found in
(2).
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1360 P. Baili et al. / European Journal of Cancer 49 (2013) 1356–1364registry data (incidence and vital status) are combined
with information on treatment (or use of health service
facilities) and follow-up (to identify recurrences, metas-
tases, second tumours, side-eﬀects of treatment, etc.) in
order to produce estimates of what EUROCHIP-3 has
designated diﬀerentiated prevalence, in which patients
are divided according to their health status as follows:
(a) cases not undergoing cancer treatment and without
distant or local relapse; (b) cases expected to die of can-
cer within a year and probably requiring terminal care
and home assistance (c) cases requiring health care or
rehabilitation, expected to die of cancer after a year.17
This has been shown to be feasible by studies per-
formed in the UK on cancer survivors in general18 and
for colorectal cancer survivors in the US by linking hos-
pital discharge data with cancer registry data.19 Similar
studies have also been performed in Italy17–20 (colon
cancer) and France21 (colorectal cancer): these studies
collected data (recurrences, metastasis and treatments)
from clinical records for samples of cases archived in
cancer registries.3.2. Indicators on measures of rehabilitation success
The panel initially sought an indicator of return to
work, since cancer survivors of working age are likely
to be unemployed more often than healthy people.22
Relatively few population-based studies have been per-
formed on proportions of cancer survivors who return
to work: the literature search found 12 articles (Table 2).
For example a Dutch study used the ArboNed Occupa-
tional Health Service register, containing sickness
absence data and medical diagnoses for 1 million Dutch
wage earners working in 33,000 companies in various
economic sectors, to estimate return to work.23–26 Can-
cer registry data were linked to census data in Fin-
land,27,28 with the Directorate of Taxes database in
Norway,29 and with the Labour Market Research Data-
base in Denmark.30,31 However, these methods of study
cannot be extended to other countries because the occu-
pational databases exploited by these studies do not
exist in most other European countries.
A feasible approach applicable to all European coun-
tries would be to perform surveys on samples of cancer
survivors extracted from cancer registry databases.
However, questionnaires would have to be compatible
across languages and cultures. Surveys of this type have
been performed in North West England (50% participa-
tion),32 Ireland (54% participation)33 and South Nether-
lands (80% participation).34
The panel extensively examined the feasibility in col-
lecting population-based data on quality of life of cancer
patients, as this was considered an important indicator
of cancer rehabilitation success. Table 3 summarises 41
European population-based studies on the quality of
life, found by the literature search. These studies weremainly conﬁned to the Netherlands, Germany, Sweden,
Iceland and France; they can be considered population-
based as they involved samples of cases extracted from
cancer registry databases, or were cross-sectional sur-
veys of the general population linked to cancer registry
databases. Various types of questionnaires were used;
those used most frequently were EORTC QLQ-C30
(European Organisation for Research and Treatment
of Cancer QLQ-C30),35 SF-36 (36-item short form
health survey),36 and HADS (Hospital Anxiety and
Depression Scale).37 Participation varied from 32% to
94% with an average participation rate equal to 72%.
The panel also drew up a list of proxy indicators of
rehabilitation needs and whether those needs are being
met. These were: speech & language therapy for head
and neck cancer patients; physiotherapy for breast can-
cer patients; dietary advice for colorectal cancer patients;
and psychological support for all cancer patients. Our lit-
erature search on these indicators found two interesting
articles. In one, data from a Swedish population-based
prostate cancer registry was linked with the National
Hospital Discharge Register and the National Pre-
scribed Drug Register to ﬁnd prostate cancer patients
who had been hospitalised for psychiatric reasons or
who used antidepressant drugs.38 In the other, a survey
(participation rate 54%) was carried out on cancer cases
extracted from the Norwegian Cancer Registry to iden-
tify the proportions using speciﬁc rehabilitation services
(physical therapy, physical training, psychological coun-
selling, supportive group sessions, admittance to conva-
lescent home, consultation with social worker and
occupational therapy) to satisfy speciﬁc needs.393.3. Indicators excluded from the ﬁnal list
The ﬁnal list excluded the following indicators origi-
nally considered by the panel: (a) list of proxy yes/no
(present/absent) indicators to assess the extent to which
cancer rehabilitation was present on political and clini-
cal agendas. Such information was considered too unre-
liable and subject to change to warrant inclusion in our
list. (b) Indicators on the presence of rehabilitation
structures and services, because the sources of informa-
tion that were found proved not to be comparable
across countries. (c) Indicators on cancer rehabilitation
funding. Here replies to the ﬁrst questionnaire made it
clear that data on funding would be diﬃcult to obtain,
and also that even if this were possible, it was unlikely
that funding data would be comparable across Euro-
pean countries.4. Discussion
All indicators of cancer rehabilitation discussed
by EUROCHIP-3 had two prerequisites: they had to
be population-based and had to be collectable by
Table 3
Results of PubMed literature search for population-based surveys on quality of life of European cancer survivors.
First author Journal Population Nation Cancer patient
population
Cancer Years from
diagnosis
EORTC
questionnaire
SF-
36
HADS Lost for external
reasons1 (%)
Question-
naires sent
Particip-
ation (%)
Jansen L J Clin Oncol 2011; 29(24) Saarland D PB-CR sample Colon
rectum
10 Yes No No – 196 69
Arndt V Eur J Cancer2006; 42(12) Saarland D PB-CR sample Colon
rectum
1–3 Yes No No – 379 82
Arndt V J Clin Oncol 2004; 22(23)
Hoyer M Acta Oncol 2011; 50(7) Cent
Sweden
S PB-CR Breast 1–2 Yes No Yes – 1573 69
Thong MS Eur J Cancer 2011; 47(12) Eindhoven NL PB-CR sample Colon 1–10 Yes Yes No 23 1135 80
Thong MS Int J Radiat Oncol Biol
Phys 2011; 81(3)
Eindhoven NL PB-CR sample Rectum 1–10 Yes Yes No 26 547 85
Aarts MJ Urology 2010; 76(5) Eindhoven NL PB-CR Prostate 5–10 No Yes No 21 964 81
Thong MS BJU Int 2010; 105(5)
Mols F BJU Int 2008; 102(11)
Mols F Cancer 2006; 107(9)
Grov EK Eur J Oncol Nurs 2011;
15(3)
Nord-
Trøndelag
N PB cross
sectional survey
Various 1–10 No No Yes 44 510 94
Skoogh J Int J Androl 2011; 34(2) Sweden S PB-CR Testis 3–26 No No Yes 4 1173 82
Schlesinger-
Raab A
Ann Oncol 2010; 21(12) Munich D PB-CR Melanoma 2 Yes No No - 1085 72
Le Corroller-
Soriano AG
Eur J Cancer Care 2011;
20(1)
France F PB cross
sectional survey
Various 2 No Yes No - 6957 64
Saevarsdottir T Cancer Nurs 2010; 33(1) Iceland ICE PB cross
sectional survey
various 0.5 No No Yes - 177 81
Agustsdottir S Br J Health Psychol 2010
Feb;15(Pt 1):51–61
Iceland ICE PB-CR Prostate 1–6 No No Yes - 383 48
Djarv T J Clin Oncol 2009; 27(12) Sweden S PB-CR Oesophagus 1–5 Yes No No 14 399 89
Rutegard M Ann Surg Oncol 2008; 15(9)
Rutegard M Br J Surg 2008 95(5)
Viklund P Eur J Cancer 2006; 42(10)
Mehnert A Psychooncology 2009;
18(12)
Hamburg D PB-CR Breast 1–6 No No No 18 1633 66
Mehnert A J Psychosom Res 2008;
64(4)
Korfage IJ Int J Rad Oncol Biol Phys
2009; 73(5)
Eindhoven NL PB-CR Cervical 2–10 Yes Yes No 6 421 69
Bouvier AM Cancer 2008; 113(4) Burgundy F PB-CR Colon
rectum
0–1 Yes No No - 209 60
Arndt V J Canc Res Clin Onc 2008;
134(12)
Saarland D PB-CR sample Breast 1–5 Yes No No - 401 78
Arndt V Cancer 2006; 107(10)
Arndt V J Clin Oncol 2005; 23(22)
Arndt V Eur J Cancer 2004; 40(5)
van de Poll-
Franse LV
Int J Rad Oncol Biol Phys
2007; 69(1)
Eindhoven NL PB-CR Endometrial 5–10 No Yes No 12 405 75
Mols F Cancer 2007; 109(8) Eindhoven NL PB-CR NH
lymphoma
5–15 No Yes No 23 360 82
(continued on next page)
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The implication is that the main source of indicators
must be population-based cancer registries. Cancer reg-
istries are present in most European countries, although
the percentage of national populations covered by can-
cer registration varies.40 Two main types of indicators
emerged from the deliberations of the panel:
(a) Indicators based on cancer prevalence. These
include total prevalence, prevalence by time from
diagnosis to prevalence date, and what EURO-
CHIP-3 has called diﬀerentiated prevalence. These
indicators were considered to be very useful prox-
ies of the burden experienced by diﬀerent groups
of cancer survivors, and assumed to have diﬀering
cancer rehabilitation needs. Cancer prevalence-
based indicators can be estimated by models using
data routinely collected by cancer registries13–15 or
– for samples of cases archived by cancer registries
– from data on diagnosis, treatment and follow-up
obtained from clinical records20,21 or hospital dis-
charge databases.17
(b) Measures of the success of rehabilitation in terms of
(i) return to work for patients of working age; (ii)
quality of life and (iii) satisfaction of rehabilitation
requirements (speciﬁcally, the panel chose to inves-
tigate speech and language therapy for head and
neck cancer survivors, physiotherapy for breast
cancer survivors, dietary therapy for colorectal can-
cer and psychological support for all cancers).
The success of rehabilitation has been estimated by a
number of national studies.23–26,29–31,38 To quantify the
rehabilitation services used by cancer survivors, cancer
registry databases can be linked with those of the struc-
tures providing rehabilitation services. For example, a
Danish study combined cancer registry and popula-
tion-based databases to assess hospitalisation for
depression as a measure of the psychological burden
experienced by cancer patients.41 However, this method
only investigates rehabilitation needs that are being met;
it can say nothing about survivors not present in rehabil-
itation service databases. Furthermore, these types of
studies cannot be performed across the whole of Europe
because the necessary databases are not uniformly pres-
ent in all countries.
One way forward would be to collect data on the can-
cer experiences of cancer survivors by getting represen-
tative samples of them to complete validated
questionnaires in all countries.
Information can also be collected through national
health surveys of the general population (although such
surveys would need to ask speciﬁcally whether the
respondent had ever been diagnosed with cancer). Sur-
veys can also be performed that are directed speciﬁcally
at cancer survivors.
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bilitation needs and facilities across Europe, the surveys
must be conducted on population-based samples of sur-
vivors (i.e. sampled from cancer registry databases).
Samples obtained from hospital databases are not repre-
sentative of the population as a whole, and are therefore
likely to provide biased and inaccurate information.
The Dutch experience with PROFILES (Patient-
Reported Outcomes Following Initial Treatment and
Long-Term Evaluation of Survivorship) is relevant
here.42 All cancer patients archived in the Eindhoven
cancer registry were asked to complete questionnaires
whose objective was to investigate the physical and psy-
chosocial impact of the cancer, and the involvement of
patients’ physicians in improving survivorship.42
Other aspects need to be considered when organising
and conducting surveys: (a) in some countries the survi-
vor may not always be aware that he/she was diagnosed
with cancer so in those situations the survivor’s general
practitioner or clinician must be contacted ﬁrst; (b)
national conﬁdentiality laws may prevent cancer
registries from contacting cancer patients; (c) if non-
participation levels are high, the survey could provide
false (biased) results. The PROFILES studies had 75–
80% participation rates,42 while other important studies
in Norway,39 the UK32 and Ireland33 had lower partici-
pation rates (50–55%). Getting patient organisations
involved might improve participation rates. Although
surveys are expensive and have the above-discussed
limits, they have the potential to provide important
information on cancer rehabilitation.
To conclude, as far as we are able to ascertain no other
studies have investigated possible indicators of cancer
rehabilitation in Europe.We are aware of the preliminary
nature of our proposals, and intend the present the study
as a starting point on which we hope other groups will
build on and improve. We believe, particularly in view
of the dramatic increase in numbers of cancer survivors
in Europe (estimated to be 18 million in 2003), that it is
important to start collecting information about cancer
survivors as soon as possible through pilot studies, to
identify their needs and whether they are being met, to
obtain information on the availability of rehabilitation
services in order to guide European cancer control poli-
cies in line with Council of Europe recommendations.EUROCHIP-3 working group on cancer rehabilitation
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